Myopathies inflammatoires
Veille bibliographique : Myopathies inflammatoires
Les articles sont classés du plus ancien au plus récent, n’hésitez pas à utiliser la barre de recherche pour filtrer les résultats par date par exemple.
| Dieval C et al. Myocarditis in Patients With Antisynthetase Syndrome: Prevalence, Presentation, and Outcomes Medicine (Baltimore). 2015 Jul;94(26):e798. | Lire le résumé |
| Ruperto N et al. Paediatric Rheumatology International Trials Organisation (PRINTO). Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juveniledermatomyositis: a randomised trial. Lancet. 2015 Nov 27. | Lire le résumé |
| Rider LG, Nistala K. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. J Intern Med. juill 2016;280(1):24‑38. | Lire le résumé |
| Habers GEA et al. Muscles in motion: a randomized controlled trial on the feasibility, safety and efficacy of an exercise training programme in children and adolescents with juvenile dermatomyositis. Rheumatol Oxf Engl. juill 2016;55(7):1251‑62. | Lire le résumé |
| Pinal-Fernandez I et al. Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann Rheum Dis. 20 sept 2016 | Lire le résumé |
| Deakin CT et al. UK Juvenile Dermatomyositis Research Group. Muscle Biopsy Findings in Combination With Myositis-Specific Autoantibodies Aid Prediction of Outcomes in Juvenile Dermatomyositis. Arthritis Rheumatol. 2016 Nov;68(11):2806-2816. 2016 Oct 9. | Lire le résumé |
| Uruha A et al. Sarcoplasmic MxA expression: A valuable marker of dermatomyositis. Neurology. 2016 Dec 30. | Lire le résumé |
| Arouche-Delaperche Louiza et al. Pathogenic Role of Anti-SRP and Anti-HMGCR Antibodies in Necrotizing Myopathies: Myofiber Atrophy and Impairment of Muscle Regeneration in Necrotizing Autoimmune Myopathies. Annals of Neurology, February 22, 2017. | Lire le résumé |
| Aggarwal R et al. 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis. mai 2017;76(5):792‐801. | Lire le résumé |
| Mamyrova G et al. Environmental factors associated with disease flare in juvenile and adult dermatomyositis.Rheumatology (Oxford). 2017 Apr 21. | Lire le résumé |
| Bachasson D et al. Physical Activity Monitoring: A Promising Outcome Measure in Idiopathic Inflammatory Myopathies. Neurology. 2017 May 31 | Lire le résumé |
| Meyer A et al. IFN-β-induced reactive oxygen species and mitochondrial damage contribute to muscle impairment and inflammation maintenance in dermatomyositis. Acta Neuropathol (Berl). 2017 Jun 16 | Lire le résumé |
| Suzuki S et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 18 août 2017 | Lire le résumé |
| Lilleker JB et al. The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis. 2017 Aug 30 | Lire le résumé |
| Lundberg IE et al. 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis Rheumatol Hoboken NJ. 2017 Oct 27 | Lire le résumé |
| Varnier GC. et al. Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care. Arthritis Care Res (Hoboken). 2017 Dec 15. | Lire le résumé |
| Allenbach Y. et al. Necrosis in anti-SRP+ and anti-HMGCR+myopathies: Role of autoantibodies and complement. Neurology. 2018 Jan 12. | Lire le résumé |
| Silverberg JI et al. Cardiovascular and cerebrovascular comorbidities of juvenile dermatomyositis in US children: an analysis of the National Inpatient Sample. Rheumatology (Oxford). 2018 Jan 24. | Lire le résumé |
| Aouizerate J, De Anton io M et al. Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis.. Rheumatology (Oxford). 2018 Feb 20 | Lire le résumé |
| Yeker RM, Pinal-Fernandez I, Kishi T, Pak K, Targoff IN, Miller FW, et al. Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis. Annals of the Rheumatic Diseases, 2018 May 7 | Lire le résumé |
| Ladislau L, Suárez-Calvet X, Toquet S, Landon-Cardinal O, Amelin D, Depp M, et al. JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain. 2018 Jun 1;141(6):1609–21 | Lire le résumé |
| Thyoka M, Adekunle O, Pilkington C, Walters S, Arthurs OJ, Humphries P, et al. Introduction of a novel magnetic resonance imaging-based scoring system for assessing disease activity in children with juvenile dermatomyositis. Rheumatology [Internet]. 2018 Jun 12 [cited 2018 Jul 27]; | Lire le résumé |
| Touat M, Maisonobe T, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology. 2018 Aug 8 | Lire le résumé |
| Touat M, Maisonobe T, Knauss S, Ben Hadj Salem O, Hervier B, Auré K, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology. 2018 Sep 4;91(10):e985– 94 | Lire le résumé |
| Mariampillai K, Granger B, Amelin D, Guiguet M, Hachulla E, Maurier F, et al. Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies. JAMA Neurology [Internet]. 2018 Sep 10 [cited 2018 Sep 25] | Lire le résumé |
| Kubo S, Todoroki Y, Nakayamada S, Nakano K, Satoh M, Nawata A, et al. Significance of nailfold videocapillaroscopy in patients with idiopathic inflammatory myopathies. Rheumatology (Oxford). 2018 Aug 28; | Lire le résumé |
| Mamyrova G, Kishi T, Targoff IN, Ehrlich A, Curiel RV, Rider LG, et al. Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis. Rheumatology. 2018 Nov 1;57(11):1956–63. | Lire le résumé |
| Bergua C, Chiavelli H, Allenbach Y, Arouche-Delaperche L, Arnoult C, Bourdenet G, et al. In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy. Annals of the Rheumatic Diseases. 2018 Oct 11;annrheumdis-2018-213518. | Lire le résumé |
| Takanashi S, Nishina N, Nakazawa M, Kaneko Y, Takeuchi T. Usefulness of serum Krebs von den Lungen-6 for the management of myositis-associated interstitial lung disease. Rheumatology [Internet]. 2019 Jan 8 [cited 2019 Jan 22]; Available from: https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/key420/5280963 | Lire le résumé |
| Pinal-Fernandez I, Amici DR, Parks CA, Derfoul A, Casal-Dominguez M, Pak K, et al. Myositis autoantigen expression correlates with muscle regeneration but not autoantibody specificity. Arthritis Rheumatol [Internet]. 12 mars 2019 [cité 26 mars 2019]; Disponible sur: http://doi.wiley.com/10.1002/art.40883 | Lire le résumé |
| Matuszak J, Blondet C, Hubelé F, Gottenberg J-E, Sibilia J, Bund C, et al. Muscle fluorodeoxyglucose uptake assessed by positron emission tomography–computed tomography as a biomarker of inflammatory myopathies disease activity. Rheumatology [Internet]. 8 mars 2019 [cité 24 avr 2019]; Disponible sur: https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/kez040/5372754 | Lire le résumé |
| Aussy A, Fréret M, Gallay L, Bessis D, Vincent T, Jullien D, et al. The IgG2 isotype of anti‐transcription intermediary factor 1‐gamma autoantibodies is a biomarker of mortality in adult dermatomyositis. Arthritis Rheumatol [Internet]. 21 mars 2019 [cité 28 mai 2019]; Disponible sur: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.40895 | Lire le résumé |
| Salem J-E, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, et al. Abatacept for Severe Immune Checkpoint Inhibitor–Associated Myocarditis. N Engl J Med. 13 juin 2019;380(24):2377 9 | Lire le résumé |
| Chen Z, Wang X, Ye S. Tofacitinib in Amyopathic Dermatomyositis–Associated Interstitial Lung Disease. N Engl J Med. 18 juill 2019;381(3):291 3 | Lire le résumé |
| Melki I, Devilliers H, Gitiaux C, Bondet V, Duffy D, Charuel J-L, et al. Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-α signalling. Rheumatology [Internet]. 22 nov 2019 [cité 20 déc 2019] | Lire le résumé |
| Tansley SL, Li D, Betteridge ZE, McHugh NJ. The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity. Rheumatology [Internet]. 6 févr 2020 [cité 25 févr 2020]; | Lire le résumé |
| Chung MP, Richardson C, Kirakossian D, Orandi AB, Saketkoo LA, Rider LG, et al. Calcinosis Biomarkers in Adult and Juvenile Dermatomyositis. Autoimmun Rev. mars 2020;102533 | Lire le résumé |
| Monseau G, Landon-Cardinal O, Stenzel W, Schoindre Y, Mariampillai K, Barete S, et al. Systematic retrospective study on 64 patients anti-Mi2 dermatomyositis: a classic skin rash with a necrotizing myositis and high risk of malignancy. J Am Acad Dermatol. mars 2020;S0190962220304801 | Lire le résumé |
| for the Juvenile Dermatomyositis Research Group (JDRG), Campanilho-Marques R, Deakin CT, Simou S, Papadopoulou C, Wedderburn LR, et al. Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients. Arthritis Res Ther [Internet]. déc 2020 [cité 22 juin 2020];22(1). | Lire le résumé |
| McElhanon KE, Young N, Hampton J, Paleo BJ, Kwiatkowski TA, Beck EX, et al. Autoantibodies targeting TRIM72 compromise membrane repair and contribute to inflammatory myopathy. J Clin Invest [Internet]. 20 juill 2020 [cité 31 juill 2020] | Lire le résumé |
| Felten R, Giannini M, Nespola B, Lannes B, Levy D, Seror R, et al. Refining myositis associated with primary Sjögren’s syndrome: data from the prospective cohort ASSESS. Rheumatology [Internet]. 11 août 2020 [cité 27 août 2020] | Lire le résumé |
| Kim H, Gunter-Rahman F, McGrath JA, Lee E, de Jesus AA, Targoff IN, et al. Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies. Arthritis Res Ther [Internet]. déc 2020 [cité 16 sept 2020];22(1) | Lire le résumé |
| Sugiyama Y, Yoshimi R, Takeno M, Kunishita Y, Kishimoto D, Kamiyama R, et al. miR-1 is a novel biomarker for polymyositis/dermatomyositis-associated interstitial lung disease. Mod Rheumatol. 2 sept 2020;30(5):878‑83. | Lire le résumé |
| Landon-Cardinal O, Baril-Dionne A, Hoa S, Meyer A, Leclair V, Bourré-Tessier J, et al. Recognising the spectrum of scleromyositis: HEp-2 ANA patterns allow identification of a novel clinical subset with anti-SMN autoantibodies. RMD Open. sept 2020;6(2):e001357. | Lire le résumé |
| Langlois V, Gillibert A, Uzunhan Y, Chabi M-L, Hachulla E, Landon-Cardinal O, et al. Rituximab and Cyclophosphamide in Antisynthetase Syndrome–related Interstitial Lung Disease: An Observational Retrospective Study. J Rheumatol. 1 nov 2020;47(11):1678‑86. | Lire le résumé |
| Papadopoulou C, Hong Y, Krol P, Al Obaidi M, Pilkington C, Wedderburn LR, et al. The Vasculopathy of Juvenile Dermatomyositis: endothelial injury, hypercoagulability, and increased arterial stiffness. Arthritis Rheumatol [Internet]. 4 janv 2021 [cité 26 janv 2021] | Lire le résumé |
| Le Voyer T, Gitiaux C, Authier F-J, Bodemer C, Melki I, Quartier P, et al. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study. Rheumatology [Internet]. 12 févr 2021 [cité 22 mars 2021]; | Lire le résumé |
| Levy D, Nespola B, Giannini M, Felten R, Severac F, Varoquier C, et al. Significance of Sjögren’s syndrome and anti-cN1A antibody in myositis patients. Rheumatology [Internet]. 11 mai 2021 [cité 28 mai 2021]; | Lire le résumé |
| 1. Siegert E, Uruha A, Goebel H-H, Preuße C, Casteleyn V, Kleefeld F, et al. Systemic sclerosis-associated myositis features minimal inflammation and characteristic capillary pathology. Acta Neuropathol (Berl). juin 2021;141(6):917‑27. 2. Ellezam B, Leclair V, Troyanov Y, Meyer A, Hudson M, Landon-Cardinal O. Capillary basement membrane reduplication in myositis patients with mild clinical features of systemic sclerosis supports the concept of ‘scleromyositis’. Acta Neuropathol (Berl). août 2021;142(2):395‑7. " | Lire le résumé |
| Huang L, Fu Q, Ye Y, Lin Y, Yan Q, Chen S. High incidence and mortality of Pneumocystis jirovecii infection in anti-MDA5-antibody-positive dermatomyositis: experience from a single center. Arthritis Res Ther. déc 2021;23(1):232. | Lire le résumé |
| Laporte A, Mariampillai K, Allenbach Y, Pasi N, Donciu V, Toledano D, et al. Idiopathic inflammatory myopathies: CT characteristics of interstitial lung disease and their association(s) with myositis-specific autoantibodies. Eur Radiol [Internet]. 13 janv 2022 [cité 28 janv 2022]; | Lire le résumé |
| Wang L-M, Yang Q-H, Zhang L, Liu S-Y, Zhang P-P, Zhang X, et al. Intravenous immunoglobulin for interstitial lung diseases of anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Rheumatol Oxf Engl. 23 déc 2021;keab928. | Lire le résumé |
| Gallay L, Fermon C, Lessard L, Weiss-Gayet M, Viel S, Streichenberger N, et al. Involvement of Type I Interferon Signaling in Muscle Stem Cell Proliferation During Dermatomyositis. Neurology. 24 mai 2022;98(21):e2108‐19 | Lire le résumé |
| Matas-García A, Guillén-Del-Castillo A, Kisluk B, Selva-O’Callaghan A, Espinosa G, Prieto-González S, et al. Clinico-pathological phenotypes of Systemic Sclerosis associated myopathy: analysis of a multicenter large cohort. Rheumatology. 17 juin 2022;keac361 | Lire le résumé |
| Topilow JS, Ospina Cardona D, Beck DB, Ferrada MA, McMahan ZH, Paik JJ. Novel genetic mutation in myositis-variant of VEXAS syndrome. Rheumatology. 17 juin 2022;keac356 | Lire le résumé |
| Rivière A, Picard C, Berastegui C, Mora VM, Bunel V, Godinas L, et al. Lung transplantation for interstitial lung disease in idiopathic inflammatory myositis: A cohort study. Am J Transplant. 3 sept 2022;ajt.17177 | Lire le résumé |
| Aggarwal R, Charles-Schoeman C, Schessl J, Bata-Csörgő Z, Dimachkie MM, Griger Z, et al. Trial of Intravenous Immune Globulin in Dermatomyositis. N Engl J Med. 6 oct 2022;387(14):1264‐78 | Lire le résumé |
| Bader-Meunier B, Breton S, Duffy D, Gitiaux C, Quartier P, Lemelle I, et al. Osteonecrosis in patients with juvenile dermatomyositis: is it associated with anti-MDA5 autoantibody? Rheumatology. 2 janv 2023;keac696 | Lire le résumé |
| Mammen AL, Amato AA, Dimachkie MM, Chinoy H, Hussain Y, Lilleker JB, et al. Zilucoplan in immunemediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial. Lancet Rheumatol. févr 2023;5(2):e67‑76. | Lire le résumé |
| Demortier J, Vautier M, Chosidow O, Gallay L, Bessis D, Berezne A, Cordel N, Schmidt J, Smail A, Duffau P, Jachiet M, Begon E, Gottlieb J, Chasset F, Graveleau J, Marque M, Cesbron E, Forestier A, Josse S, Kluger N, Beauchene C, Le Corre Y, Pagis V, Rigolet A, Guillaume-Jugnot P, Authier F, Guilain N, Streichenberger N, Leonard-Louis S, Boussouar S, Landon-Cardinal O, Benveniste O, Allenbach Y. Anti-SAE autoantibody in dermatomyositis: original comparative study and review of the literature. Rheumatology (Oxford). 2023 Apr 3:kead154. doi: 10.1093/rheumatology/kead154. Epub ahead of print. PMID: 37010495. | Lire le résumé |
| Pecher AC, Hensen L, Klein R, Schairer R, Lutz K, Atar D, et al. CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome. JAMA. 27 juin 2023;329(24):2154‑62 | Lire le résumé |